Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
A fixed-dose combination psychotropic drug. **Flupentixol** is a thioxanthene antipsychotic (dopamine receptor antagonist) used for its anxiolytic and antidepressant properties at low doses. **Melitracen** is a tricyclic antidepressant (TCA) that acts as a norepinephrine and serotonin reuptake inhibitor, providing mood-elevating and anxiolytic effects.
## Primary Indications
Treatment of mild to moderate anxiety, depression, and apathy (psychosomatic disorders). Note: This combination is not approved by the FDA or EMA; availability varies significantly by region.
## Adult Dosing
* **Standard dose:** 1 tablet (0.5 mg flupentixol / 10 mg melitracen) taken orally once or twice daily (morning/noon).
* **Maximum dose:** Typically 4 tablets daily.
* **Administration:** Avoid evening dosing due to the potential for insomnia (melitracen).
## Pediatric Dosing
* **Safety and efficacy:** Not established. Use is generally **contraindicated** in children and adolescents due to the risk of TCA-related cardiovascular events and flupentixol-related extrapyramidal symptoms.
## Dose Adjustments
* **Geriatric:** Start with the lowest possible dose (e.g., 1 tablet once daily) due to increased sensitivity to anticholinergic side effects and orthostatic hypotension.
* **Hepatic/Renal Impairment:** Reduce frequency or avoid; clinical data are insufficient for specific titration protocols.
## Contraindications
* Hypersensitivity to either component.
* Recent myocardial infarction or cardiac conduction defects (bundle branch blocks).
* Acute alcohol, barbiturate, or opioid intoxication.
* Blood dyscrasias, circulatory collapse, or coma.
* Concomitant use with MAO inhibitors (must allow 14-day washout).
## Adverse Effects
* **Common:** Dry mouth, insomnia, restlessness, dizziness, tremors, and blurred vision.
* **Serious:** Extrapyramidal symptoms (dystonia, parkinsonism), tachycardia, QT interval prolongation, urinary retention, and agranulocytosis (rare).
## Key Drug Interactions
* **CNS Depressants:** Potentiates effects of alcohol, sedatives, and hypnotics.
* **Antihypertensives:** Risk of additive postural hypotension; blunts effects of guanethidine or clonidine.
* **CYP2D6 Inhibitors:** May increase melitracen plasma levels, increasing toxicity risk.
* **Anticholinergics:** Increases risk of paralytic ileus, hyperthermia, and confusion.
## Monitoring
* Baseline and periodic ECG assessments (QT prolongation monitoring).
* Blood pressure (orthostatic checks).
* Monitoring for emergence of movement disorders (AIMS scale).
* Assess mood/suicidal ideation, especially during initial therapy.
## Clinical Pearls
* **Duration:** Should be used for the shortest duration possible. Long-term use without periodic re-evaluation is discouraged.
* **Withdrawal:** Discontinue gradually to prevent withdrawal symptoms (e.g., nausea, insomnia, headache).
* **Activation:** The combination is inherently stimulating; it is not indicated for agitated or highly anxious patients who require sedation.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice protocols vary by country and institution. Always verify specific dosing, safety warnings, and contraindications against current local formulary guidelines and the official product manufacturer’s summary of product characteristics (SmPC) before prescribing.
